TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34803872

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) plus standard medical therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 80
Study: 36440639

Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33369276

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 40 IU subcutaneously twice weekly for 15 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 80 IU subcutaneously twice weekly for 15 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 80 IU subcutaneously 3 times weekly for 15 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 0.5 mg subcutaneously for 5 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 0.75 mg subcutaneously for 5 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 1 mg subcutaneously for 5 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 1 mg intramuscularly for 5 days
Number of subjects: 2
Study: 32716299

Group type: EXPERIMENTAL
Intervention: ReZone (mHealth intervention)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Management as usual (control)
Number of subjects: 409
Study: 36354026

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Sham remote ischaemic conditioning
Number of subjects: 3033
Study: 34048940

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA, 30 min)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 35102743

Group type: EXPERIMENTAL
Intervention: 6-week cervicovestibular rehabilitation program combined with SLAE
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6-week SLAE program alone
Number of subjects: 60
Study: 33414435

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered orally 1 hour before exposure sessions
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo administered orally 1 hour before exposure sessions
Number of subjects: 46
Study: 32571614

Group type: EXPERIMENTAL
Intervention: Caloric restriction and usual activity
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combined diet and exercise
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study: 35704106

Group type: COMPARATOR
Intervention: Transurethral fulguration (TUF)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transurethral fulguration plus hydrodistension (TUF+HD)
Number of subjects: 52
Study: 32280055

Group type: EXPERIMENTAL
Intervention: 45 g/day of high‐amylose maize (RS2) for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isocaloric amount of rapidly digestible starch amylopectin (CTL) for 12 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: RS2
Number of subjects: 59
Study: 36684395

Group type: EXPERIMENTAL
Intervention: evriMED500® MERM device
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard in-person DOT
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: MERM device usability
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall satisfaction and adherence correlation
Number of subjects: 109
Study: 32967430

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 10
Study: 35834792

Group type: EXPERIMENTAL
Intervention: POCUS-guided NGT insertion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard technique (control)
Number of subjects: 120
Study: 33517896

Group type: EXPERIMENTAL
Intervention: Inhaled high molecular weight hyaluronan (HMW-HA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 36456969

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment combined with routine treatment
Number of subjects: 222

Group type: COMPARATOR
Intervention: Routine treatment (medication and rehabilitation)
Number of subjects: 222
Study: 33830956

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Symptomatic SARS-CoV-2 infection
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection (asymptomatic and symptomatic)
Number of subjects: 1454
Study: 34237250

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 187
Study: 33218305

Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT) via telehealth
Number of subjects: 57

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 57
Study: 35387675

Group type: EXPERIMENTAL
Intervention: Phone call reminders one week before the appointment
Number of subjects: 1311

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1311
Study: 32737923

Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Insulin Lispro (LIS)
Number of subjects: 138
Study: 32466912

Group type: EXPERIMENTAL
Intervention: kcal information
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: PA information
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: kcal + PA information
Number of subjects: 480

Group type: COMPARATOR
Intervention: blind condition
Number of subjects: 480
Study: 35863836

Group type: EXPERIMENTAL
Intervention: Low-dose trimethoprim-sulfamethoxazole (10 mg/kg/day of TMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care trimethoprim-sulfamethoxazole (15 mg/kg/day of TMP)
Number of subjects: 0
Study: 33800711

Group type: EXPERIMENTAL
Intervention: Stochastic algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage greedy randomized adaptive search (GRASP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage stochastic sample greedy (SSD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GRASP
Number of subjects: 0
Study: 32902647

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) during radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy without androgen deprivation therapy (ADT)
Number of subjects: 0
Study: 36050264

Group type: EXPERIMENTAL
Intervention: Nomograms based on clinical prognostic factors, IVIM‐DWI parameters, and MRI-derived radiomics
Number of subjects: 115
Study: 33403890

Group type: EXPERIMENTAL
Intervention: Blood pressure target <140/90 mmHg
Number of subjects: 15245

Group type: EXPERIMENTAL
Intervention: Blood pressure target <130/80 mmHg
Number of subjects: 15245

Group type: COMPARATOR
Intervention: Overall cardiovascular outcomes
Number of subjects: 15245

Group type: COMPARATOR
Intervention: Primary cardiac endpoint
Number of subjects: 15245
Study: 32000822

Group type: EXPERIMENTAL
Intervention: Enterosgel®
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 35483733

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study: 33512755

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Omarigliptin for 52 weeks
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Omarigliptin for 36 weeks (switched from placebo at Week 16)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 184
Study: 35504446

Group type: EXPERIMENTAL
Intervention: Benzalkoniumchloride (BAC) mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0
Study: 32827113

Group type: EXPERIMENTAL
Intervention: SCM muscle flap
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBD muscle flap
Number of subjects: 15

Group type: COMPARATOR
Intervention: No reconstruction (NR)
Number of subjects: 15
Study: 33734030

Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA)
Number of subjects: 66
Study: 35810336

Group type: EXPERIMENTAL
Intervention: Exercise intervention (high‐intensity interval exercise at 80% of VO2max, with 1‐minute high‐intensity intervals at 95% of VO2max, twice a week for 3 months)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise intervention (high‐intensity interval exercise)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist (no exercise)
Number of subjects: 32
Study: 32361799

Group type: EXPERIMENTAL
Intervention: Educational-religious classes for 15 sessions
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided)
Number of subjects: 152
Study: 35429480

Group type: EXPERIMENTAL
Intervention: Ganaxolone (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 101
Study: 33998590

Group type: EXPERIMENTAL
Intervention: Job stress dimensions (Demand-Control-Social Support and Effort-Reward Imbalance models)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: High psychological demands, low decision latitude, low social support, high effort-reward ratio
Number of subjects: 495
Study: 32800391

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oropharyngeal Exercises (OE)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 33445967

Group type: EXPERIMENTAL
Intervention: Seeing Hanks' disclosure post
Number of subjects: 682

Group type: COMPARATOR
Intervention: Not seeing Hanks' disclosure post
Number of subjects: 682
Study: 34022169

Group type: EXPERIMENTAL
Intervention: Holter-ECG recording for up to 7 days in hospital (intervention group)
Number of subjects: 3465

Group type: COMPARATOR
Intervention: Usual diagnostic procedures for atrial fibrillation detection (control group)
Number of subjects: 3465
Study: 32700944

Group type: EXPERIMENTAL
Intervention: Classroom behavior management training program
Number of subjects: 1818
Study: 35372439

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 280
Study: 33768391

Group type: EXPERIMENTAL
Intervention: mobile app program
Number of subjects: 110

Group type: COMPARATOR
Intervention: supervised health program
Number of subjects: 110
Study: 35258786

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Number of subjects: 26
Study: 36418565

Group type: EXPERIMENTAL
Intervention: DHA-supplement (250 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DHA-supplement
Number of subjects: 116
Study: 34157024

Group type: EXPERIMENTAL
Intervention: six weekly group-format stroke risk reduction self-management training sessions
Number of subjects: 246

Group type: COMPARATOR
Intervention: enhanced treatment control (information on cardiovascular risk)
Number of subjects: 246
Study: 32171028

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) during hospital stay
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) post-discharge
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Control group (no comprehensive medication reviews)
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Intervention group (CMRs)
Number of subjects: 2637
Study: 35850961

Group type: EXPERIMENTAL
Intervention: 20-30 mg oral sustained-release morphine daily for 4 weeks
Number of subjects: 45
Study: 33934542

Group type: EXPERIMENTAL
Intervention: Clinical phenogroups identified through unsupervised machine learning
Number of subjects: 1693

Group type: COMPARATOR
Intervention: LVEF-based classifications
Number of subjects: 1693
Study: 34252106

Group type: EXPERIMENTAL
Intervention: wMel-infected Ae. aegypti mosquito deployments
Number of subjects: 373000
Study: 32551828

Group type: EXPERIMENTAL
Intervention: PARO (individual, nonfacilitated, 30‐min sessions with the robotic seal PARO, 5 days per week for 6 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 43
Study: 34237681

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Number of subjects: 6
Study: 32146218

Group type: EXPERIMENTAL
Intervention: ACT-DL (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active control (n = 28)
Number of subjects: 55
Study: 36429610

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rigid Taping (RT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo Taping (C)
Number of subjects: 90
Study: 33109480

Group type: EXPERIMENTAL
Intervention: Contemporary neuroscience approach (pain neuroscience education, stress management, cognition-targeted exercise therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional physical therapy (biomedically focused education, graded and active exercise therapy)
Number of subjects: 120
Study: 35478103

Group type: EXPERIMENTAL
Intervention: Group A: 50 μg misoprostol escalated to 100 μg and then to 200 μg every 4 h (max 600 μg daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Group B: 25 μg misoprostol followed by 100 μg every 4 h (max 300 μg daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 124
Study: 35968287

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular acupressure (A&AA)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 360
Study: 33310170

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Midnight fasting group (NPO group)
Number of subjects: 88
Study: 36137672

Group type: EXPERIMENTAL
Intervention: Abbreviated antiplatelet therapy (APT) regimen (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants)
Number of subjects: 4579

Group type: EXPERIMENTAL
Intervention: Abbreviated antiplatelet therapy (APT) regimen
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Nonabbreviated antiplatelet therapy (APT) regimen (DAPT for minimum 3 months)
Number of subjects: 4579
Study: 33422431

Group type: EXPERIMENTAL
Intervention: Remote management through WeChat app
Number of subjects: 180

Group type: COMPARATOR
Intervention: Traditional medical treatment (Control)
Number of subjects: 180
Study: 34578811

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolytes (C + E)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2 g/L dipeptide (alanyl‐glutamine)‐electrolytes (AG + E)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Electrolytes only (E)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AG + E and E
Number of subjects: 19
Study: 33178291

Group type: EXPERIMENTAL
Intervention: Knowledge assessment
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Attitude assessment
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Infection prevention practice assessment
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Age category 20–29
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Single participants
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Greater than ten years of working experience
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Positive attitude
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Availability of water at working area
Number of subjects: 373
Study: 35446628

Group type: EXPERIMENTAL
Intervention: ADT plus orteronel (300 mg oral twice daily)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: ADT with bicalutamide (50 mg oral once daily)
Number of subjects: 1279
Study: 34702785

Group type: EXPERIMENTAL
Intervention: 12-month activity tracker intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study: 32792359

Group type: EXPERIMENTAL
Intervention: High IO-score (24-gene RNA signature)
Number of subjects: 96
Study: 33508375

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 100
Study: 32249193

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 45
Study: 34738284

Group type: EXPERIMENTAL
Intervention: Dr. Erica (digital intervention with 3 months of multimedia messaging)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dr. Erica (digital intervention)
Number of subjects: 146
Study: 34126270

Group type: EXPERIMENTAL
Intervention: LAAO with same-day discharge and early cessation of antithrombotic therapy
Number of subjects: 229
Study: 35691258

Group type: EXPERIMENTAL
Intervention: Pistacia atlantica subsp. Kurdica herbal capsule for 2 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo capsule for 2 months
Number of subjects: 58
Study: 33722477

Group type: EXPERIMENTAL
Intervention: Individualized follitropin delta dosing (AMH <15 pmol/l: 12 µg/day; AMH ≥15 pmol/l: 0.10–0.19 µg/kg/day; minimum 6 µg/day; maximum 12 µg/day)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Conventional follitropin beta dosing (150 IU/day for the first 5 days, with potential subsequent dose adjustments)
Number of subjects: 347
Study: 33566703

Group type: EXPERIMENTAL
Intervention: HXLPE cup
Number of subjects: 58

Group type: COMPARATOR
Intervention: ConvPE cup
Number of subjects: 58
Study: 32505701

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme
Number of subjects: 164

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 164
Study: 32796876

Group type: EXPERIMENTAL
Intervention: Smoking initiation (genetically predicted)
Number of subjects: 1232091
Study: 33592303

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32150141

Group type: EXPERIMENTAL
Intervention: FOOTFIT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FOOTFIT+
Number of subjects: 24
Study: 34958531

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening, kallikrein panel, and multiparametric MRI
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Additional testing (kallikrein panel and MRI) after PSA
Number of subjects: 399
Study: 33501854

Group type: EXPERIMENTAL
Intervention: Virtual Workshop (VW) group using multimedia software program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actual Workshop (AW) group participating in a face-to-face workshop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both VW and AW groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VW teachers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both teacher groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups of students
Number of subjects: 0
Study: 32664064

Group type: EXPERIMENTAL
Intervention: Gwakhyangjeonggi-san (GJS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 33357672

Group type: EXPERIMENTAL
Intervention: 30°C 30%RH for 8 hours
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 30°C 80%RH for 8 hours
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 4 hours exposure
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 30°C 30%RH
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: -15°C uncontrolled RH
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 8 hours exposure
Number of subjects: 240
Study: 32483056

Group type: EXPERIMENTAL
Intervention: 3 sessions per week of acupuncture (TSWA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 session per week of acupuncture (OSWA)
Number of subjects: 60
Study: 36198130

Group type: EXPERIMENTAL
Intervention: PlasmaJet Surgical Device
Number of subjects: 327

Group type: COMPARATOR
Intervention: Conventional CRS
Number of subjects: 327
Study: 33790400

Group type: EXPERIMENTAL
Intervention: Isometric exercises (maximum clenching for 10 seconds, repeated five times, twice daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (tapping teeth at arbitrary speed for 10 seconds, repeated five times, twice daily for 4 weeks)
Number of subjects: 0
Study: 35673945

Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercise (SSE) and postural correction exercises (PCE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postural correctional exercises (PCE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercise (SSE)
Number of subjects: 60
Study: 33491582

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Paracetamol (1.5 g)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg) and Paracetamol (1.5 g)
Number of subjects: 29
Study: 35277461

Group type: EXPERIMENTAL
Intervention: MVI-816 and pembrolizumab every 3 weeks (arm 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MVI-816 every 2 weeks and pembrolizumab every 4 weeks (arm 4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MVI-816 and pembrolizumab (both arms)
Number of subjects: 40
Study: 33939479

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36199120

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) plus BEACON smartphone application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Problem-solving therapy (PST) alone
Number of subjects: 0
Study: 33888117

Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (CGM) sensor (iPro™2) worn for 7 days, followed by medical consultation and educational session
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (CGM)
Number of subjects: 302